Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) is a pioneering clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. Agenus is steadfast in its mission to develop innovative immunological therapies aimed at leveraging the body's immune system to combat cancer and other diseases. The company’s diverse product pipeline includes immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc., and vaccine adjuvants through its subsidiary SaponiQx Inc. These products are bolstered by in-house capabilities such as current good manufacturing practice (cGMP) manufacturing and a clinical operations platform.
Agenus has developed several key product candidates, including botensilimab (AGEN1811), a next-generation Fc-engineered CTLA-4 antibody, and balstilimab, a PD-1 antibody. They are currently under investigation for their potential to treat various cancers, particularly difficult-to-treat solid tumors.
The company has achieved significant milestones, including the initiation of various clinical trials for botensilimab and balstilimab. Notably, in April 2024, Agenus announced a one-for-twenty reverse stock split of its issued and outstanding common stock to increase its stock price and meet Nasdaq Capital Market listing requirements. This move is part of a strategic plan to enhance future financing and qualify for inclusion in the Russell Indices.
In its ongoing pursuit of innovative cancer treatments, Agenus recently announced Phase 1 trial results demonstrating encouraging survival rates in patients with metastatic colorectal cancer. The Phase 2 data is expected to be submitted to a major medical conference in the latter half of 2024.
Agenus also engages in strategic partnerships to accelerate its development programs. For instance, a recent agreement with Ligand Pharmaceuticals secures a $100 million capital infusion, specifically aimed at supporting the clinical development and launch readiness of the BOT/BAL combination therapy.
The team at Agenus comprises scientists, researchers, biotechnologists, physicians, and business professionals united by the shared goal of achieving breakthroughs in cancer treatment. This collaborative spirit ensures that Agenus remains at the forefront of transformative cancer therapies, aiming to enhance patient outcomes and extend lives.
For more information, visit www.agenusbio.com or follow @agenus_bio on social media.
Agenus (NASDAQ: AGEN) announced its participation in the ASCO 2023 Annual Meeting from June 2-6 in Chicago, IL, where it will present clinical data from key trials. An oral presentation on June 5 will detail a Phase 2 trial of balstilimab and zalifrelimab combined with doxorubicin for advanced sarcomas. Additionally, a poster discussion on June 3 will cover the monotherapy results of AGEN2373, a CD137 agonist, in advanced solid tumors. Abstracts will be available on May 25. Balstilimab and zalifrelimab are designed to enhance immune response against cancer, while AGEN2373 targets T and NK cells with reduced liver toxicity risks.
Agenus (NASDAQ: AGEN), an immuno-oncology company, will release its first-quarter 2023 financial results on May 9, 2023, before market opening. A conference call will follow at 8:30 a.m. ET to discuss results and corporate updates. The call can be accessed via dial-in or a live webcast from the Company’s events page. Agenus is focused on developing therapies that leverage the immune system for cancer treatment, utilizing various therapeutics, including antibody agents and cell therapies. The Company aims to expand the reach of cancer immunotherapy by pursuing a range of combination therapies. For more information, visit their website.
Agenus (NASDAQ: AGEN), an immuno-oncology company, will feature Chairman and CEO Dr. Garo Armen at two upcoming investor conferences. The HC Wainwright BioConnect Investor Conference is set for May 2, 2023, at 3:30 PM ET in New York City, where Dr. Armen will participate in a fireside chat. Additionally, he will engage in 1x1 meetings at the EF Hutton Global Conference on May 10, 2023. A live webcast of the fireside chat will be available on the company’s website, with a replay posted afterward. Agenus aims to improve cancer treatment through innovative therapies that enhance the immune response. The company operates advanced antibody discovery platforms and a GMP manufacturing facility to support clinical programs.
Agenus Inc. (NASDAQ: AGEN) has received Fast Track Designation from the FDA for its combination therapy of botensilimab (AGEN1181) and balstilimab (AGEN2034) targeting non-MSI-H colorectal cancer patients. This designation is significant for heavily pretreated patients who have limited treatment options. The ongoing Phase 2 trial aims to show better effectiveness than current standards. Positive results from earlier trials revealed a 23% overall response rate and a 63% 12-month survival rate, significantly outperforming existing treatments. Dr. Steven O’Day highlighted the unmet medical need and the potential for Priority Review from the FDA. Moreover, the company is advancing research in various solid tumor indications.
Agenus has declared a dividend of 5 million shares of its subsidiary, MiNK Therapeutics, to shareholders on record as of April 17, 2023. The distribution aims to provide additional value and direct ownership in MiNK, which is engaged in developing allogeneic T cell therapies for cancer. The shares will be distributed no earlier than April 27, 2023, and no later than May 17, 2023. Fractional shares will be compensated in cash based on MiNK's closing price on the record date. This initiative reflects Agenus' confidence in MiNK's solid tumor programs and its commitment to enhancing shareholder value.
Agenus (NASDAQ: AGEN) announced promising results from a Phase 1b study on botensilimab, a CTLA-4 antibody, combined with balstilimab, a PD-1 antibody, targeting recurrent platinum-resistant ovarian cancer. Presenting at the SGO 2023 Annual Meeting, the study reported a remarkable 33% overall response rate with 67% disease control among 24 evaluable patients. This efficacy surpasses past PD-(L)1/CTLA-4 combinations that showed only 3-10% response rates. The patients involved were heavily pre-treated, suggesting the combination's transformative potential. Agenus is expanding its clinical trials further across various cancer types.
Agenus Inc. provided a corporate update and reported Q4 and full year 2022 financial results, highlighting its lead asset, botensilimab, which has shown promising overall response rates in various cancers. Key results include a 23% response rate in microsatellite stable colorectal cancer and 50% in PD-(L)1 refractory non-small cell lung cancer. A confirmatory Phase 3 trial for MSS CRC is planned for 2023. The company announced existing collaborations could yield $2.7B in milestones and royalties. However, Agenus reported a net loss of $74 million for Q4, totaling $231 million for the year, alongside a cash balance of $193 million.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
What does Agenus Inc. specialize in?
Where is Agenus Inc. headquartered?
What are the key products of Agenus Inc.?
What recent strategic financial move did Agenus make?
What significant agreement did Agenus secure recently?
What are some recent clinical trial achievements of Agenus?
What is the focus of Agenus' product candidates?
Who are part of the Agenus team?
How does Agenus support its product development?
Where can investors find more information about Agenus?
